Literature DB >> 24126434

Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.

Richard D Dinnen1, Yuehua Mao, Wanglong Qiu, Nicholas Cassai, Vesna N Slavkovich, Gwen Nichols, Gloria H Su, Paul Brandt-Rauf, Robert L Fine.   

Abstract

Pancreatic cancer cell lines with mutated ras underwent an alternative form of cell death (aponecrosis) when treated concomitantly with clinically achievable concentrations of arsenic trioxide, ascorbic acid, and disulfiram (Antabuse; AAA). AAA's major effects are mediated through generation of intracellular reactive oxygen species (ROS) and more than 50% decline in intracellular ATP. N-acetyl cysteine and a superoxide dismutase mimetic prevented aponecrosis and restored intracellular ATP levels. DIDS (4,4'-diisothiocyanatostilbene-2, 2' disulfonic acid), the pan- Voltage-Dependent Anion Channel (VDAC), -1, 2, 3 inhibitor and short hairpin RNA (shRNA) to VDAC-1 blocked cell death and ROS accumulation. In vivo exposure of AAA led to a 62% reduction in mean tumor size and eliminated tumors in 30% of nude mice with PANC-1 xenografts. We concluded that early caspase-independent apoptosis was shifted to VDAC-mediated "targeted" aponecrosis by the addition of disulfiram to arsenic trioxide and ascorbic acid. Conceptually, this work represents a paradigm shift where switching from apoptosis to aponecrosis death pathways, also known as targeted aponecrosis, could be utilized to selectively kill pancreatic cancer cells resistant to apoptosis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126434      PMCID: PMC4318573          DOI: 10.1158/1535-7163.MCT-13-0234

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  40 in total

1.  Does cancer therapy trigger cell suicide?

Authors:  E Finkel
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

2.  Effect of copper and disulfiram combination therapy on the macular mouse, a model of Menkes disease.

Authors:  Wattanaporn Bhadhprasit; Hiroko Kodama; Chie Fujisawa; Tomoko Hiroki; Eishin Ogawa
Journal:  J Trace Elem Med Biol       Date:  2012-06-02       Impact factor: 3.849

3.  2,7-dichlorofluorescin oxidation and reactive oxygen species: what does it measure?

Authors:  W Jakubowski; G Bartosz
Journal:  Cell Biol Int       Date:  2000       Impact factor: 3.612

4.  Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.

Authors:  P Westervelt; R A Brown; D R Adkins; H Khoury; P Curtin; D Hurd; S M Luger; M K Ma; T J Ley; J F DiPersio
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

5.  Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model.

Authors:  Michael Bouvet; Jinwei Wang; Stephanie R Nardin; Rounak Nassirpour; Meng Yang; Eugene Baranov; Ping Jiang; A R Moossa; Robert M Hoffman
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

6.  Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?

Authors:  T Bachleitner-Hofmann; B Gisslinger; E Grumbeck; H Gisslinger
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

Review 7.  Mitochondria, oxygen free radicals, and apoptosis.

Authors:  S Raha; B H Robinson
Journal:  Am J Med Genet       Date:  2001

8.  Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis.

Authors:  L Formigli; L Papucci; A Tani; N Schiavone; A Tempestini; G E Orlandini; S Capaccioli; S Z Orlandini
Journal:  J Cell Physiol       Date:  2000-01       Impact factor: 6.384

Review 9.  Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.

Authors:  R M Hoffman
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

10.  VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release.

Authors:  M Madesh; G Hajnóczky
Journal:  J Cell Biol       Date:  2001-12-10       Impact factor: 10.539

View more
  10 in total

Review 1.  Crosstalk between calcium and reactive oxygen species signaling in cancer.

Authors:  Nadine Hempel; Mohamed Trebak
Journal:  Cell Calcium       Date:  2017-01-18       Impact factor: 6.817

Review 2.  Disulfiram: a novel repurposed drug for cancer therapy.

Authors:  Chen Lu; Xinyan Li; Yongya Ren; Xiao Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-10       Impact factor: 3.333

Review 3.  Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.

Authors:  Maricela Viola-Rhenals; Kush R Patel; Laura Jaimes-Santamaria; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Curr Med Chem       Date:  2018-02-12       Impact factor: 4.530

Review 4.  Is Arsenic Exposure a Risk Factor for Metabolic Syndrome? A Review of the Potential Mechanisms.

Authors:  Pablo Pánico; Myrian Velasco; Ana María Salazar; Arturo Picones; Rosa Isela Ortiz-Huidobro; Gabriela Guerrero-Palomo; Manuel Eduardo Salgado-Bernabé; Patricia Ostrosky-Wegman; Marcia Hiriart
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-16       Impact factor: 6.055

Review 5.  Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.

Authors:  Varda Shoshan-Barmatz; Yakov Krelin; Anna Shteinfer-Kuzmine; Tasleem Arif
Journal:  Front Oncol       Date:  2017-07-31       Impact factor: 6.244

Review 6.  Disulfiram in glioma: Literature review of drug repurposing.

Authors:  Shiyu Zhong; Xudong Zhang; Kunhang Li; Guojun Liu; Lishuai Li; Shanwei Tao; Bowen Zheng; Weichen Sheng; Ziyin Ye; Qichen Xing; Qingqing Zhai; Lijie Ren; Ying Wu; Yijun Bao
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

7.  Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative and anti-apoptotic bioactivities.

Authors:  Jie Zhao; Yingzi Ming; Qiquan Wan; Shaojun Ye; Song Xie; Yi Zhu; Yanfeng Wang; Zibiao Zhong; Ling Li; Qifa Ye
Journal:  Exp Ther Med       Date:  2014-02-21       Impact factor: 2.447

8.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

9.  Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia.

Authors:  Sujit Suklabaidya; Biswajit Das; Syed Azmal Ali; Sumeet Jain; Sharada Swaminathan; Ashok K Mohanty; Susen K Panda; Pujarini Dash; Subhankar Chakraborty; Surinder K Batra; Shantibhusan Senapati
Journal:  Oncotarget       Date:  2016-07-05

10.  Ascorbic Acid Sensitizes Colorectal Carcinoma to the Cytotoxicity of Arsenic Trioxide via Promoting Reactive Oxygen Species-Dependent Apoptosis and Pyroptosis.

Authors:  Wei Tian; Zhuo Wang; Nan-Nan Tang; Jia-Tong Li; Yu Liu; Wen-Feng Chu; Bao-Feng Yang
Journal:  Front Pharmacol       Date:  2020-02-21       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.